[go: up one dir, main page]

DE69823984D1 - Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden - Google Patents

Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden

Info

Publication number
DE69823984D1
DE69823984D1 DE69823984T DE69823984T DE69823984D1 DE 69823984 D1 DE69823984 D1 DE 69823984D1 DE 69823984 T DE69823984 T DE 69823984T DE 69823984 T DE69823984 T DE 69823984T DE 69823984 D1 DE69823984 D1 DE 69823984D1
Authority
DE
Germany
Prior art keywords
hiv
synthesis
hepatitis virus
virus activity
oxaselenolane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823984T
Other languages
English (en)
Other versions
DE69823984T2 (de
Inventor
F Schinazi
K Chu
Jinfa Du
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
University of Georgia Research Foundation Inc
Original Assignee
Emory University
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, University of Georgia Research Foundation Inc filed Critical Emory University
Publication of DE69823984D1 publication Critical patent/DE69823984D1/de
Application granted granted Critical
Publication of DE69823984T2 publication Critical patent/DE69823984T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69823984T 1997-03-19 1998-03-19 Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden Expired - Lifetime DE69823984T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4126597P 1997-03-19 1997-03-19
US41265P 1997-03-19
PCT/US1998/005517 WO1998041522A1 (en) 1997-03-19 1998-03-19 Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides

Publications (2)

Publication Number Publication Date
DE69823984D1 true DE69823984D1 (de) 2004-06-24
DE69823984T2 DE69823984T2 (de) 2005-05-12

Family

ID=21915638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823984T Expired - Lifetime DE69823984T2 (de) 1997-03-19 1998-03-19 Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden

Country Status (10)

Country Link
US (3) US6071922A (de)
EP (1) EP0970078B1 (de)
CN (1) CN1196701C (de)
AT (1) ATE267198T1 (de)
AU (1) AU739240B2 (de)
CA (1) CA2287370C (de)
DE (1) DE69823984T2 (de)
EA (2) EA005097B1 (de)
ES (1) ES2221164T3 (de)
WO (1) WO1998041522A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69923338T2 (de) * 1998-11-02 2006-04-06 Gilead Sciences, Inc., Foster City Kombinationstherapie zur behandlung von hepatitis b infektionen
NO20001904L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretanfilmer fremstilt ved elektrolytisk utfelling fra polyuretandispersjoner
NO20001903L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretan-filmer fremstilt fra polyuretan-dispersjoner
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1720840B1 (de) * 2004-02-03 2016-02-03 Emory University Verfahren zur herstellung von 1,3-dioxolannukleosiden
US20080154351A1 (en) 2006-09-06 2008-06-26 Leewood Alan R Stents With Biodegradable Connectors And Stabilizing Elements
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
KR101021294B1 (ko) 2010-10-11 2011-03-11 공주대학교 산학협력단 신규한 셀레닐 메틸 우라실 화합물 및 이를 이용한 방사선 치료 증진제 및 의약 조성물
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP3226924A4 (de) * 2014-11-03 2018-08-01 Bovin, Nicolai Vladimirovich Antimikrobielle oberflächenbehandlung

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3732761A1 (de) * 1986-09-30 1988-03-31 Zahnradfabrik Friedrichshafen Fahrzeuggetriebe mit integrierter bremse
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
AU625018B2 (en) * 1989-12-20 1992-06-25 Biotech Australia Pty Limited Variants of pai-2
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
EP1142891B1 (de) * 1991-03-06 2007-05-02 Emory University Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
CN1196701C (zh) 2005-04-13
US6071922A (en) 2000-06-06
EA199900843A1 (ru) 2000-04-24
EA005097B1 (ru) 2004-10-28
EA200100494A3 (ru) 2002-02-28
CA2287370C (en) 2010-02-09
EA200100494A1 (ru) 2001-10-22
ES2221164T3 (es) 2004-12-16
AU739240B2 (en) 2001-10-04
WO1998041522A1 (en) 1998-09-24
DE69823984T2 (de) 2005-05-12
US6590107B1 (en) 2003-07-08
CN1255132A (zh) 2000-05-31
US6197777B1 (en) 2001-03-06
EA001920B1 (ru) 2001-10-22
CA2287370A1 (en) 1998-09-24
EP0970078A1 (de) 2000-01-12
EP0970078B1 (de) 2004-05-19
ATE267198T1 (de) 2004-06-15
AU6866598A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
DE69823984D1 (de) Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
DE69635656D1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
LV10054A (lv) Pretvirusu antibakterials savienojums un lietosanas metode
DK0666749T3 (da) Enantiomert rene beta-D-dioxalannukleosider med selektiv antihepatitis B virus aktivitet
EP0984013A3 (de) Antivirus Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
MY107843A (en) Anti-viral compounds.
BG100455A (en) Hiv protease inhibitors
ES8802616A1 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
ATE346651T1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
TW371662B (en) Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives
DK615788D0 (da) Nucleosidforbindelser til anvendelse mod virale infektioner
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
DE69324244D1 (de) Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
MY137298A (en) Therapeutic nucleosides
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
EP0316592A3 (de) 3'-Fluor-2',3'-dideoxyuridin und seine therapeutische Verwendung
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV

Legal Events

Date Code Title Description
8364 No opposition during term of opposition